This EUTOS 2022 (European Treatment and Outcome Study) work sought to investigate BCR::ABL1 mutations and other genetic alterations associated with asciminib resistance in CML myeloblastic clones and to assess the sensitivity of asciminib-resistant CML cells to treatment in vitro and on a preclinical mouse model. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.